|
Discovery | Pre-Clinical | Phase I | Phase II | Phase III | Manufacturing | Funding | Intellectual Property | Regulatory | EB Programs
We organize events to enable the startup community to meet, share, and discuss their topics of interest.
Perspectives on Concept to Clinic, End-to-End Process Development, Capital Access.
Read more and download white paper>
The goal of the event was to provide guidance on the journey from drug discovery to commercial manufacturing and to engage in dialogue with the emerging biotechnology community focused on developing immunotherapies. Conference topics included regulatory affairs, fundraising opportunities and partnership development
Download white paper>
The first annual Emerging Biotech Executive Summit established an open dialog within the biotech community and connected executives in alliance management, in-licensing and venture funding. This white paper provides key meeting takeaways, highlighting perspectives on early stage investments and partnerships as well as how to build value, credibility and recognition to your company's clinical stage products or services.
Download white paper>
Would you like to be contacted about upcoming events? Please leave your details and we will contact you.
Advance Biotech Grant Program – Accelerating Therapeutic Development in Life Science
The Life Science business of MilliporeSigma is expanding its commitment to the global biotech community with its Advance Biotech Grant Program. Through the newly expanded grant program, every six months, three recipients around the globe will be awarded a total of €200,000 in free services and products to address their process development challenges. In total, six companies will benefit from the Advance Biotech Grant Program each year. Press Release
Bringing your molecule to market. As part of our commitment to meet the needs of the life science community, we’ve developed several programs that recognize stand-out emerging biotech companies. These programs are designed to support biotech start-ups and medium sized companies in solving their current bioprocess development challenges to bring the next generation of molecules to market.
Learn more about the advantages to work with one source on your mAb, linker/ payload supplies and conjugation services.
Review the current dynamics in the RNA therapeutics/vaccines market with a focus on process development and manufacturing strategies.
Learn more on points to consider for successful tech transfers with a focus on cGMP training requirements.
Establishing an open dialog within the biotech community....
A report from the The Economist Intelligence Unit sponsored by MilliporeSigma.
This paper, which incorporates the results of a survey of 254 pharmaceutical executives from around the world and a range of interviews with industry experts, explores in detail global pharmaceutical companies' growth strategies and their plans for managing the associated risks.
Research. Development. Production.
We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.
